drugset / Trial / NCT01254526
Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with taxane-based chemotherapy regimens utilized in patients with locally recurrent or metastatic breast cancer.
Timeline
- Start
- 2010-12
- Primary completion
- 2012-07
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apitolisib | Small molecule | — | Oral |
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |